4 completed, 1 terminated. 3 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
| Phase 1 | 2 | Completed 1, Terminated 1 |
Follow abrilumab: new trials by email Literature Review of abrilumab trials Research Report on abrilumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MEDI7183 Phase 2 Study in Japanese Ulcerative Colitis Patients MEDI7183 low dose, MEDI7183 medium dose, MEDI7183 high dose - Ulcerative Colitis | Phase 2 | Completed | AstraZeneca | 44 | 2013-11-21 | 2019-07-05 |
| Abrilumab (AMG 181) in Adults With Moderate to Severe Crohn's Disease Abrilumab, Placebo - Crohn's Disease | Phase 2 | Completed | Amgen | 254 | 2012-12-04 | 2019-06-27 |
| Abrilumab (AMG 181) in Adults With Moderate to Severe Ulcerative Colitis Abrilumab, Placebo - Ulcerative Colitis | Phase 2 | Completed | Amgen | 359 | 2012-11-16 | 2019-06-27 |
| Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181. AMG 181, Placebo for AMG 181 - Ulcerative Colitis, Crohn's Disease | Phase 1 | Completed | Amgen | 43 | 2011-02-01 | 2015-03-17 |
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181 in Healthy Subjects and Subjects With Mild to Moderate Ulcerative Colitis Amg 181 - Ulcerative Colitis | Phase 1 | Terminated | Amgen | 72 | 2010-07-01 | 2013-07-25 |
Colitis, Ulcerative (4) · Crohn Disease (2) · Inflammatory Bowel Diseases (1)
Amgen (4) · AstraZeneca (1)
United States (4) · Australia (3) · Austria (2) · Belgium (2) · Canada (2) · Czechia (2) · Denmark (2) · France (2) · Germany (2) · Hungary (2) · Netherlands (2) · Switzerland (2) · United Kingdom (2) · Estonia (1) · Greece (1)
Ki Rito, Study Physician (1) · Toshifumi Hibi, Director and Professor (1)